Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Postexposure treatment of Marburg virus infection.

Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, Grolla A, Feldmann H.

Emerg Infect Dis. 2010 Jul;16(7):1119-22. doi: 10.3201/eid1607.100159.

2.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Nov 22;218(suppl_5):S582-S587. doi: 10.1093/infdis/jiy293.

3.

Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment.

Daddario-DiCaprio KM, Geisbert TW, Ströher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H.

Lancet. 2006 Apr 29;367(9520):1399-404.

PMID:
16650649
4.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Ströher U, Fritz EA, Hensley LE, Jones SM, Feldmann H.

Vaccine. 2008 Dec 9;26(52):6894-900. doi: 10.1016/j.vaccine.2008.09.082. Epub 2008 Oct 18.

5.

A single shot against Ebola and Marburg virus.

Baize S.

Nat Med. 2005 Jul;11(7):720-1. No abstract available.

PMID:
16015361
6.

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81. doi: 10.1093/infdis/jir349. Review.

7.

Good news for Marburg virus workers.

Becker S.

Lancet. 2006 Apr 29;367(9520):1373-4. No abstract available.

PMID:
16650630
8.

Marburg vaccine shows promise: offers postexposure protection in monkeys.

Hampton T.

JAMA. 2006 May 24;295(20):2346. No abstract available.

PMID:
16720816
9.

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A.

Virology. 1998 Nov 10;251(1):28-37.

10.

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H.

J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.

11.

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW.

Nat Med. 2005 Jul;11(7):786-90. Epub 2005 Jun 5.

PMID:
15937495
12.

Progress in filovirus vaccine development: evaluating the potential for clinical use.

Falzarano D, Geisbert TW, Feldmann H.

Expert Rev Vaccines. 2011 Jan;10(1):63-77. doi: 10.1586/erv.10.152. Review.

13.

Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys.

Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA.

J Biotechnol. 1996 Jan 26;44(1-3):111-8.

PMID:
8717394
14.

[Ebola and Marburg viruses: the humans strike back].

Alazard-Dany N, Ottmann Terrangle M, Volchkov V.

Med Sci (Paris). 2006 Apr;22(4):405-10. Review. French.

15.

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation.

Marzi A, Menicucci AR, Engelmann F, Callison J, Horne EJ, Feldmann F, Jankeel A, Feldmann H, Messaoudi I.

Front Immunol. 2019 Jan 22;9:3071. doi: 10.3389/fimmu.2018.03071. eCollection 2018.

16.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S.

Nat Med. 2010 Sep;16(9):991-4. doi: 10.1038/nm.2202. Epub 2010 Aug 22.

PMID:
20729866
17.

Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Mire CE, Geisbert JB, Agans KN, Satterfield BA, Versteeg KM, Fritz EA, Feldmann H, Hensley LE, Geisbert TW.

PLoS One. 2014 Apr 23;9(4):e94355. doi: 10.1371/journal.pone.0094355. eCollection 2014.

18.

Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.

Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S.

Expert Rev Vaccines. 2008 May;7(4):417-29. doi: 10.1586/14760584.7.4.417.

PMID:
18444889
19.

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.

Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S.

Vaccine. 2004 Sep 3;22(25-26):3495-502.

PMID:
15308377
20.

Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.

Martins K, Carra JH, Cooper CL, Kwilas SA, Robinson CG, Shurtleff AC, Schokman RD, Kuehl KA, Wells JB, Steffens JT, van Tongeren SA, Hooper JW, Bavari S.

Viral Immunol. 2015 Feb;28(1):62-70. doi: 10.1089/vim.2014.0071.

PMID:
25514232

Supplemental Content

Support Center